Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Lobe Sciences Ltd

Healthcare CA LOBE

0.09CAD
0.00(0%)

Last update at 2026-06-23T16:41:00Z

Day Range

0.090.09
LowHigh

52 Week Range

0.020.10
LowHigh

Fundamentals

  • Previous Close 0.09
  • Market Cap28.30M
  • Volume7900
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.09161M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.24931M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax -4.86161M -4.38773M -4.50235M -12.25285M -23.84448M
Minority interest 0.43M 0.00000M - - -
Net income -4.42766M -4.42073M -4.70735M -12.25285M -9.65841M
Selling general administrative 3.54M 1.78M 2.88M 3.69M 4.94M
Selling and marketing expenses - - - - -
Gross profit 0.00000M 0.13M 0.82M 0.00000M -
Reconciled depreciation 0.00000M 0.08M 0.04M 0.01M 0.00000M
Ebit - - - -4.12321M -6.31620M
Ebitda - - - -4.11299M -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -4.17632M -2.11611M -3.35939M -4.12321M -6.31620M
Other operating expenses - - - - -
Interest expense 0.60M 0.19M 0.04M 0.00000M 0.00000M
Tax provision 0.00000M 0.03M 0.20M 0.00000M -1.02369M
Interest income 0.02M 0.00000M - - -
Net interest income -0.57792M -0.18665M -0.03864M 0.00000M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -1.02369M
Total revenue 0.00000M 0.14M 0.84M 0.00000M 0.00000M
Total operating expenses 4.18M 2.25M 4.20M 4.12M 6.32M
Cost of revenue 0.00000M 0.00176M 0.02M 0.00000M -
Total other income expense net -0.10737M -2.08497M -1.10432M -8.12964M -17.52828M
Discontinued operations - - - - 13.16M
Net income from continuing ops -4.86161M -4.42073M -4.70735M -12.25285M -22.82079M
Net income applicable to common shares - - - -12.25285M -9.65841M
Preferred stock and other adjustments - - - - -
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 7.59M 0.26M 2.30M 1.75M 12.10M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - 0.20M
Total liab 2.70M 3.37M 2.46M 1.30M 0.80M
Total stockholder equity 2.36M -3.11439M -0.16013M 0.45M 11.29M
Deferred long term liab - - - - -
Other current liab 0.21M 0.60M - - -
Common stock - - - 25.22M 24.84M
Capital stock 34.71M 30.61M 27.62M 25.22M 24.84M
Retained earnings -39.25384M -40.10310M -35.68238M -30.97503M -18.47417M
Other liab - - - - -
Good will - - - - -
Other assets - - - - 0.07M
Cash 5.85M 0.24M 0.14M 0.91M 1.14M
Cash and equivalents - - - - -
Total current liabilities 2.43M 2.27M 2.46M 1.30M 0.80M
Current deferred revenue - - - - -
Net debt - 1.51M 0.19M - -
Short term debt - - - - -
Short long term debt - 0.64M 0.33M - -
Short long term debt total - - - - -
Other stockholder equity - - - 4.90M 3.68M
Property plant equipment - - - - -
Total current assets 7.59M 0.26M 0.32M 1.04M 9.67M
Long term investments - - 0.00000M 0.68M 0.96M
Net tangible assets - - - 0.42M 11.25M
Short term investments 1.69M - - 0.00000M 6.28M
Net receivables 0.05M 0.00934M 0.01M 0.02M 1.76M
Long term debt 0.27M 1.11M - - -
Inventory - 0.00000M 0.02M 0.00000M -
Accounts payable 1.98M 0.78M 1.92M 1.20M 0.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 1.36M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 1.98M 0.71M 2.43M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Investments -1.68669M 0.00000M 0.00000M 1.74M -0.44541M
Change to liabilities - - - 0.50M 0.24M
Total cashflows from investing activities - - - - 1.07M
Net borrowings 0.17M 0.56M 0.34M 0.00000M -0.08782M
Total cash from financing activities 8.76M 0.56M 0.95M 2.50M 4.92M
Change to operating activities - - - 0.17M 0.09M
Net income -4.42766M -4.42073M -4.70735M -12.25285M -9.65841M
Change in cash 5.62M 0.10M -0.76863M -0.23430M 0.97M
Begin period cash flow 0.24M 0.14M 0.91M 1.14M 0.17M
End period cash flow 5.85M 0.24M 0.14M 0.91M 1.14M
Total cash from operating activities -1.41712M -0.46229M -1.71864M -2.73073M -5.03736M
Issuance of capital stock 0.35M 0.00000M 0.68M 0.00000M 5.17M
Depreciation 0.00000M 0.08M 0.04M 0.01M 0.01M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.00000M 0.00176M 0.02M 0.00000M -
Change to account receivables - - - 0.18M -0.14319M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - -0.04288M -0.19833M
Change to netincome - - - 8.66M 4.44M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.16M 1.33M 1.52M 0.85M 0.19M
Stock based compensation 0.53M 0.27M 0.30M 0.62M 0.92M
Other non cash items 0.60M 0.19M 1.10M 7.04M 11.15M
Free cash flow -1.41712M -0.46229M -1.71864M -2.73073M -5.03736M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LOBE
Lobe Sciences Ltd		 - -% 0.09 - - 2.44 15.58 5.75 1.64
DRUG
Bright Minds Biosciences Inc		 -0.85 0.90% 94.04 - - - 13.50 -0.098
METX
METX		 - -% 1.99 - - - 72.00
TELI
Telescope Innovations Corp.		 0.06 7.23% 0.89 - - 4.32 6.45 4.32 -1.62
DTC
Defence Therapeutics Inc		 -0.04 7.27% 0.51 - - - 89.80 -9.991

Reports Covered

Stock Research & News

View All

Profile

Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The company was founded in 2018 and is headquartered in Vancouver, Canada.

Lobe Sciences Ltd

1771 Robson Street, Vancouver, BC, Canada, V6G 3B7

Key Executives

Name Title Year Born
Dr. Frederick Dominick Sancilio M.S., Ph.D. Chairman & CEO 1950
Mr. Charles F. Goulburn M.B.A. President 1962
Mr. Yong Yao EVP & Chief Financial Officer 1968
Mr. Maghsoud Dariani B.S., M.S. Chief Science Officer 1954
Dr. Herman Williams M.B.A., M.D., M.P.H. CEO Alt, Inc 1960
Mr. Mirza Rahimani Chief Financial Officer 1980
Dr. Robert Miller Ph.D. Senior Vice President of Quality and Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions